Skip to content

In silico identification of flavonoid inhibitors targeting cholera toxin from Vibrio cholerae: Molecular docking, ADMET profiling, and molecular dynamics simulation.

Sep 2026 · Computational biology and chemistry · Vol 126 Pt 1, pp. 109387 · 0 citations · 45 references
Medicine

TL;DR

Findings show that kaempferol is a viable lead compound for cholera toxin suppression and serve as the foundation for future antitoxin medication development and experimental validation.

Abstract

An integrated computational strategy was used to identify potential inhibitors of the NAD (+)-arginine ADP-ribosyl transferase of cholera toxin. The target protein structure was obtained from the UniProt database and validated using PROCHECK. The potential binding pockets were predicted using DeepSite. A total of 50 flavonoids were screened using structure based virtual screening (VS), of which Kaempferol (-9.1 kcal/mol) and Taxifolin (-8.9 kcal/mol) were identified as potential inhibitors. Molecular interaction studies indicated that kaempferol had a substantially larger interaction network (greater number of hydrogen bonds, pi-pi interactions and hydrophobic interactions) than taxifolin. ADMET and toxicity profiling for each compound indicated that both compounds had favorable drug-like properties including high GI absorption, low BBB penetrability, and acceptable toxicity profiles. 100 ns molecular dynamics analyses showed stable binding for both ligands. Kaempferol had faster equilibration times, less flexible protein, and less solvent exposure than taxifolin. Additionally, MM-GBSA binding free energy analyses further corroborate the binding affinity of kaempferol/taxifolin was stronger (-36.28 vs -30.62 Kcal/mol binding affinity). Collectively, these findings show that kaempferol is a viable lead compound for cholera toxin suppression and serve as the foundation for future antitoxin medication development and experimental validation.

View source

Similar papers

Review Open access Aug 2026

Integrated molecular docking, toxicity prediction, and molecular dynamics simulations studies to identify potential antimalarial candidates targeting enoyl-acyl carrier protein reductase enzyme

A cost-effective computational workflow for prioritizing ENR inhibitors is demonstrated, providing a foundation for the development of novel antimalarial agents and highlighting Cd3 and Cd5 as the most promising candidates for further development.

Abozur Mohamed Mohyeldin Khalil, Carlos Eliel Maya-Ramírez, A. A. Razzak Mahmood et al. · 0 citations
Open access Aug 2026

Identification of Potential SARS-CoV-2 Main Protease (MPro) Inhibitors Through Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation Approaches

The findings suggest that Lig-1, followed by Lig-3, may serve as promising computational lead compounds targeting SARS-CoV-2 MPro, representing promising candidates for further experimental validation.

Mohd Yasir Khan, Farah Maarfi, A. Shah et al. · 0 citations
Open access Jul 2026

Identifying and Evaluating Flavonoids as Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro/3CL) Through Docking and Molecular Dynamics

Findings highlight glycosylated flavonoids as promising scaffolds for future structure-based optimization and provide structural insights to guide experimental validation.

Getulio Flores-Tlalpa, L. Domínguez-Ramírez, Luis Márquez-Domínguez et al. · 0 citations
Open access Sep 2026

Investigation of ABL Kinase Inhibitory Potential of Bioactive From Juglans Regia: Molecular Docking, Pharmacophore Modelling and Molecular Dynamics Simulation Study

Objective: The present study aimed to investigate the potential of phytoconstituents of Juglans regia derived from IMPPAT database as inhibitors of the Abelson tyrosine kinase (c-Abl), using in silico tools. Methods: Physicochemical and pharmacokinetic properties were predicted using QikProp, while toxicity profiles we...

Z. Fathima C., J. James, Sindhu T. J. et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.